EU MDR Clinical Evaluation Report: A Practical Guide (2026)

What is the EU MDR Clinical Evaluation Report

The Clinical Evaluation Report (CER) is the structured document that demonstrates a medical device's clinical safety, performance, and benefit-risk profile under EU MDR (Regulation 2017/745). It is mandatory for every device placed on the EU market regardless of class — though the depth and evidence required scale with risk class.

The CER serves three distinct audiences. For your Notified Body reviewing a Class IIa, IIb, or III device, the CER is the central technical-file document they audit to decide whether your conformity assessment passes. For your internal quality management system, the CER is a living document that anchors clinical risk management, post-market surveillance, and design changes. For competent authorities investigating an incident or recall, the CER is the document that establishes whether you understood the risks of your device when you placed it on the market.

MEDDEV 2.7/1 rev 4 vs MDR Article 61: what changed

Before EU MDR became applicable in May 2021, clinical evaluation was governed by the MEDDEV 2.7/1 revision 4 guidance document (published 2016). MEDDEV 2.7/1 rev 4 was not legally binding but functioned as the de facto standard that Notified Bodies enforced. EU MDR Article 61 and Annex XIV now codify clinical evaluation requirements in legally binding form, with several substantive tightenings:

The practical implication: if your existing CER was prepared under MEDDEV 2.7/1 rev 4 and has not been re-assessed against MDR Article 61 requirements, it is almost certainly insufficient for MDR submission. The most common failure is equivalence claims that satisfied MEDDEV but do not meet MDR's tighter criteria.

CER structure — the 6 phases and 14 sections

EU MDR clinical evaluation follows the 5-stage framework inherited from MEDDEV 2.7/1, expanded with explicit MDR requirements:

Phase 0 — Plan (Clinical Evaluation Plan, CEP)

Document the scope of the evaluation, the device description and intended purpose, the clinical questions to be answered, the state of the art definition, the search strategy, the equivalence approach (if used), and the methodology for data appraisal. The CEP must be approved before clinical evaluation begins.

Phase 1 — Identification of relevant data

Systematic literature search using documented protocols (database, search strings, inclusion/exclusion criteria, screening process). Pre-clinical, clinical investigation, post-market data, and equivalent-device data are all relevant sources.

Phase 2 — Appraisal of identified data

Critical assessment of each data source — methodological quality, relevance to the specific device and intended use, weight given in the overall evaluation. This is the phase where Notified Bodies focus most attention; weak appraisal is the most common rejection driver.

Phase 3 — Analysis of clinical data

Synthesis across all appraised sources. Conclusions on clinical safety, clinical performance, benefit-risk balance, and acceptability of residual risks. Gap analysis: what is not yet known, and how PMCF will address it.

Phase 4 — Documentation in the CER

Compile the CER document itself, typically structured in 14 sections following MDCG 2020-13 guidance or similar Notified Body templates. Internal review, version control, and management sign-off.

Phase 5 — Post-market loop

Once the device is on the market, PMS and PMCF data feed back into the next CER update. The CER is a living document, not a one-time submission.

The equivalence pathway and why it's now harder

Under MEDDEV 2.7/1 rev 4, manufacturers could often satisfy clinical evaluation requirements by demonstrating equivalence to an already-approved device on the European market. EU MDR Article 61 tightened this pathway substantially. Equivalence now requires demonstration across three dimensions — clinical, technical, and biological — with specific tests applied to each.

For Class III implantable devices, the bar is particularly high. Article 61(5) requires that the manufacturer claiming equivalence have contractual access to the full technical documentation of the comparator device. In practice, this means equivalence claims against a competitor's product are now nearly impossible — you would need a written agreement giving you access to their technical file. For non-implantable Class III, the bar is slightly lower but still significantly tighter than under MEDDEV.

Clinical data sufficiency by device class

EU MDR does not prescribe a fixed quantity of clinical data. Sufficiency is a judgment call, made against the state of the art and the device's risk profile. In practice, the bar scales as follows:

Class I (non-sterile, non-measuring)

Self-declared conformity, no Notified Body involvement. CER is still required but generally light — focused on demonstrating the device's intended use, safety profile from existing literature, and post-market surveillance plan.

Class IIa

Notified Body review of technical documentation. CER typically draws on a combination of literature evidence and post-market data from predicate devices. Bench testing, biocompatibility, and design-related clinical claims usually suffice.

Class IIb

Higher scrutiny, particularly for active devices and devices in contact with the cardiovascular or central nervous systems. Notified Bodies typically expect either equivalence demonstration backed by published clinical evidence, or pre-market clinical investigation data on the device itself.

Class III (non-implantable)

Clinical investigation on the device itself is the default expectation. Equivalence may be acceptable for some categories but increasingly rare. The Notified Body consults with the relevant Expert Panel for additional review.

Class III implantable

Clinical investigation on the device itself is mandatory unless extraordinary equivalence circumstances apply. Multi-arm, randomized clinical investigation data is typical for novel devices. SSCP (Summary of Safety and Clinical Performance) is required and publicly accessible.

CER, PMCF and PSUR — the post-market loop

The CER does not stand alone. It connects to three other documents in the EU MDR ecosystem, and the connections matter:

• PMCF Plan (Post-Market Clinical Follow-up Plan) — defines how you will gather additional clinical data once the device is on the market, addressing the gaps your CER identified. Mandatory for most device classes; PMCF outputs feed back into CER updates.
• PSUR (Periodic Safety Update Report) — Class IIa updated every 2 years, Class IIb and III updated annually. Aggregates vigilance data, PMS findings, and PMCF outputs. PSUR conclusions feed into CER updates.
• SSCP (Summary of Safety and Clinical Performance) — public-facing summary for Class III and implantable. Lay summary in patient-facing language alongside professional summary.

The four documents form a coherent system. CER establishes the baseline. PMCF Plan defines how you'll add to it. PSUR aggregates what you find. SSCP communicates it publicly. Notified Bodies look at all four together; weakness in one undermines the others.

What Notified Bodies actually look for

From conversations with manufacturers who have submitted CERs to TÜV SÜD, BSI, DEKRA, GMED and other Notified Bodies, the recurring areas of focus are:

1. Methodological rigor of the literature search. Documented search strategy, replicable queries, screening with two independent reviewers, justification for exclusions. A weak search appears in almost every rejection letter.
2. Critical appraisal of evidence quality. Each cited study assessed on study design, sample size, follow-up duration, relevance to the specific device and indication. Generic "this study supports our claim" language is a red flag.
3. State of the art definition. The CER must establish the current clinical standard against which the device is benchmarked. This is more than a literature summary — it requires articulating what good clinical outcomes look like in the relevant therapeutic area.
4. Equivalence justification. When equivalence is claimed, the three-dimensional analysis (clinical, technical, biological) must be explicit and documented. Lazy equivalence is the fastest path to rejection.
5. Benefit-risk analysis. Quantified where possible. Acceptable residual risks must be justified, not just listed.
6. Integration with PMS/PMCF. The CER's gap analysis must logically connect to the PMCF Plan's data-collection objectives.

Common rejection reasons and how to avoid them

In the experience of EU MDR consulting practices and Notified Body audit feedback, the recurring rejection drivers are:

1. Equivalence claims that don't meet MDR's tighter criteria

Fix: re-assess equivalence under MDR Article 61(5), particularly the access-to-technical-documentation requirement for Class III. If equivalence fails, plan a clinical investigation.

2. Literature search not systematic or not reproducible

Fix: document a search protocol upfront (databases, terms, dates, screeners). Run it as if it were a systematic review for a peer-reviewed journal.

3. Outdated clinical data

Fix: data older than 5 years requires explicit justification of continued relevance. Re-run searches periodically.

4. Generic state-of-the-art statements

Fix: state of the art must reference specific clinical practice guidelines, current standard-of-care interventions, and benchmark clinical outcomes. Cite the consensus documents (ESC, NICE, AAOS, etc.) relevant to your therapeutic area.

5. PMCF Plan disconnected from CER gaps

Fix: the PMCF Plan should explicitly address each clinical question the CER left open. Reviewers test this connection routinely.

6. Benefit-risk analysis without quantitative framing

Fix: where possible, quantify benefits (event rates, time-to-effect, durability) and risks (adverse event rates from your data and comparator data). Qualitative-only analysis is a weakness even when not a rejection.

Realistic timeline and cost

For manufacturers planning an EU MDR submission, the CER timeline is often underestimated. Realistic ranges:

• Class IIa, simple device: 8-12 weeks from CEP approval to draft CER, plus 4-6 weeks for internal review.
• Class IIb, moderate complexity: 14-20 weeks, plus 6-8 weeks for review and potential PMCF feedback integration.
• Class III, non-implantable: 6-9 months if equivalence is viable; longer if clinical investigation is required.
• Class III implantable, novel device: 12-24 months including clinical investigation completion.

Cost ranges, based on consulting practice quotes:

• Class IIa: €15,000 – €40,000
• Class IIb: €30,000 – €80,000
• Class III, equivalence-based: €60,000 – €120,000
• Class III, clinical investigation: €200,000+ depending on study design

These are CER preparation costs only — they do not include the clinical investigation itself, the Notified Body fees, or the broader regulatory submission overhead.

Consultant vs in-house CER preparation

Small and mid-size medical device companies — typical clients for the European distributor partner-selection work — often face a build-versus-buy decision on CER preparation. The trade-offs:

In-house preparation

Advantages: deeper knowledge of the device, lower cash cost, internal team builds long-term regulatory capability. Disadvantages: high opportunity cost for clinical and regulatory staff, risk of unfamiliarity with current MDR norms and Notified Body expectations, longer timeline.

External consultant

Advantages: speed (specialists do this every week), pattern recognition for what Notified Bodies accept, ability to scale across multiple devices in parallel. Disadvantages: cash cost, dependence on the consultant for future updates, risk of generic "templated" CERs that lack device-specific depth.

Hybrid approach

Most successful manufacturers in our experience use a hybrid: external consultant for the structure, literature search methodology, and Notified Body submission strategy; internal clinical and regulatory team for device-specific content, benefit-risk analysis, and ongoing maintenance. Best of both, at a moderate cost premium over pure in-house.

Where this fits in your European market entry

The CER is one component of a broader European go-to-market plan that includes Notified Body selection, distributor partner identification, country-specific registration, reimbursement strategy, and ongoing PMS. The directory at MedicalDeviceDistributors.com covers the distribution side — finding the partners who will sell the device into European hospitals once your regulatory pathway is clear.

For the regulatory work itself, manufacturers typically engage either a specialized regulatory consulting firm (TÜV SÜD Regulatory Affairs, RQM+, Cisema, BSI Regulatory Services) or a hybrid market-entry advisor that combines regulatory navigation with commercial strategy. Fractio operates in the latter category, supporting European medical device launches end-to-end from regulatory roadmap to signed distributor agreements.